

# Interactions with HDV Treatment

Charts created April 2024. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

	Bulevirtide
<b>Anaesthetics and muscle relaxants</b>	
Bupivacaine	◆
Cisatracurium	◆
Desflurane	◆
Dexmedetomidine	◆
Ephedrine	◆
Etidocaine	◆
Halothane	◆
Isoflurane	◆
Ketamine	◆
Nitrous oxide	◆
Propofol	◆
Sevoflurane	◆
Tetracaine	◆
Thiopental	◆
Tizanidine	◆
<b>Analgesics</b>	
Acetoclofenac	◆
Alfentanil	■
Aspirin	◆
Buprenorphine	◆
Celecoxib	◆
Codeine	◆
Dexketoprofen	◆
Dextropropoxyphene	◆
Diamorphine	◆
Diclofenac	◆
Diflunisal	◆
Dihydrocodeine	◆
Etoricoxib	◆
Fentanyl (Prescribed)	■
Flurbiprofen	◆
Hydrocodone	■
Hydromorphone	◆
Ibuprofen	◆
Indometacin	◆
Ketoprofen	◆
Mefenamic acid	◆
Meloxicam	◆
Metamizole (Dipyrone)	◆
Methadone	◆
Morphine	◆
Naproxen	◆
Oxycodone	■
Paracetamol	◆
Pethidine (Meperidine)	◆
Piroxicam	◆
Tapentadol	◆
Tramadol	◆
<b>Anthelmintics</b>	
Albendazole	◆
Ivermectin	◆
Nicosamide	◆
Oxamniquine	◆
Praziquantel	◆
Pyrantel	◆
<b>Antiarrhythmics</b>	
Amiodarone	■
Bepidil	◆
Digoxin	◆
Disopyramide	◆
Dofetilide	■
Dronedaron	■
Flecainide	◆
Lidocaine (Lignocaine)	◆
Mexiletine	◆
Propafenone	◆
Quinidine	■
Vernakalant	◆

For personal use only. Not for distribution.

	Bulevirtide
<b>Antibacterials</b>	
Amikacin	◆
Amoxicillin	◆
Ampicillin	◆
Azithromycin	◆
Aztreonam	◆
Bedaquiline	■
Benzyloxyphenylpenicillin	◆
Capreomycin	◆
Cefaclor	◆
Cefadroxil	◆
Cefalexin	◆
Cefazolin	◆
Cefixime	◆
Cefotaxime	◆
Cefradine	◆
Ceftaroline	◆
Ceftazidime	◆
Ceftriaxone	◆
Cefuroxime	◆
Chloramphenicol	◆
Ciprofloxacin	◆
Clarithromycin	◆
Clavulanic acid	◆
Clindamycin	◆
Clofazimine	◆
Cloxacillin	◆
Cycloserine	◆
Dapsone	◆
Delamanid	◆
Ertapenem	◆
Erythromycin	◆
Ethambutol	◆
Flucloxacillin	◆
Gentamicin	◆
Imipenem	◆
Isoniazid	◆
Levofloxacin	◆
Linezolid	◆
Lymecycline	◆
Meropenem	◆
Methenamine	◆
Metronidazole	◆
Moxifloxacin	◆
Nitrofurantoin	◆
Norfloxacin	◆
Ofloxacin	◆
Penicillin V	◆
Piperacillin	◆
Pivmecillinam	◆
Pretomanid	◆
Pyrazinamide	◆
Rifabutin	◆
Rifampicin	◆
Rifapentine	◆
Rifaximin	▲
Spectinomycin	◆
Streptomycin	◆
Sulfadiazine	◆
Tazobactam	◆
Telithromycin	◆
Temocillin	◆
Tetracyclines	◆
Ticarcillin	◆
Timethoprim/Sulfamethoxazole	◆
Troleandomycin	◆

For personal use only. Not for distribution.

	Bulevirtide
<b>Anticoagulant, Anti-Platelet &amp; Fibrinolytic</b>	
Abciximab	◆
Acenocoumarol	◆
Anagrelide	◆
Apixaban	■
Caplacizumab	◆
Clopidogrel	◆
Dabigatran	◆
Dalteparin	◆
Danaparoid	◆
Dipyridamole	◆
Edoxaban	◆
Enoxaparin	◆
Fluindione	◆
Fondaparinux	◆
Heparin	◆
Phenprocoumon	■
Prasugrel	◆
Rivaroxaban	■
Streptokinase	◆
Ticagrelor	◆
Ticlopidine	◆
Tinzaparin	◆
Warfarin	◆
<b>Anticonvulsants</b>	
Carbamazepine	■
Clonazepam	◆
Eslicarbazepine	◆
Ethosuximide	◆
Gabapentin	◆
Lacosamide	◆
Lamotrigine	◆
Levetiracetam	◆
Oxcarbazepine	◆
Perampanel	◆
Phenobarbital	◆
Phenytoin	◆
Pregabalin	◆
Primidone	◆
Retigabine	◆
Rufinamide	◆
Sultiame	◆
Tiagabine	◆
Topiramate	◆
Valproic acid (Divalproex)	◆
Vigabatrin	◆
Zonisamide	◆

For personal use only. Not for distribution.

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HDV Treatment

Charts created April 2024. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

	Bulevirtide
<b>Antidepressants</b>	
Agomelatine	◆
Amitriptyline	◆
Bupropion	◆
Citalopram	◆
Clomipramine	◆
Desipramine	◆
Desvenlafaxine	◆
Dosulepin	◆
Doxepin	◆
Duloxetine	◆
Escitalopram	◆
Fluoxetine	◆
Fluvoxamine	◆
Imipramine	◆
Lithium	◆
Maprotiline	◆
Mianserin	◆
Milnacipran	◆
Mirtazapine	◆
Moclobemide	◆
Nefazodone	◆
Nortriptyline	◆
Paroxetine	◆
Reboxetine	■
Sertraline	◆
Tianeptine	■
Trazodone	◆
Trimipramine	◆
Venlafaxine	◆
Vortioxetine	◆
<b>Antidiabetics</b>	
Acarbose	◆
Albiglutide	◆
Alogliptin	◆
Canagliflozin	◆
Dapagliflozin	◆
Dulaglutide	◆
Empagliflozin	◆
Exenatide	◆
Glibenclamide (Glyburide)	■
Gliclazide	◆
Glimepiride	◆
Glipizide	◆
Insulin	◆
Linagliptin	◆
Liraglutide	◆
Lixisenatide	◆
Metformin	◆
Nateglinide	■
Pioglitazone	◆
Repaglinide	■
Rosiglitazone	◆
Saxagliptin	◆
Semaglutide	◆
Sitagliptin	◆
Tirzepatide	◆
Tolbutamide	◆
Vildagliptin	◆

	Bulevirtide
<b>Antifungals</b>	
Amphotericin B	◆
Anidulafungin	◆
Caspofungin	◆
Fluconazole	◆
Flucytosine	◆
Griseofulvin	◆
Isavuconazole	◆
Itraconazole	◆
Ketoconazole	●
Miconazole	◆
Nystatin	◆
Posaconazole	◆
Terbinafine	◆
Voriconazole	◆
<b>Antihæmorrhagics</b>	
Avatrombopag	◆
Eltrombopag	◆
Tranexamic acid	◆
<b>Antihistamines</b>	
Astemizole	■
Bilastine	◆
Cetirizine	◆
Chlorphenamine	◆
Desloratadine	◆
Diphenhydramine	◆
Doxylamine	◆
Ebastine	■
Fexofenadine	■
Hydroxyzine	◆
Levocetirizine	◆
Loratadine	◆
Promethazine	◆
Terfenadine	■
<b>Antimigraine Agents</b>	
Almotriptan	◆
Dihydroergotamine	■
Eletriptan	◆
Eptinezumab	◆
Erenumab	◆
Ergotamine	■
Fremanezumab	◆
Frovatriptan	◆
Galcanezumab	◆
Methylergonovine	■
Naratriptan	◆
Pizotifen	◆
Rizatriptan	◆
Sumatriptan	◆
Zolmitriptan	◆

	Bulevirtide
<b>Antiprotozoals</b>	
Amodiaquine	◆
Artemether	◆
Artemisinin	◆
Artesunate	◆
Atovaquone	◆
Chloroquine	◆
Dihydroartemisinin	◆
Doxycycline	◆
Halofantrine	◆
Hydroxychloroquine	◆
Lumefantrine	◆
Mefloquine	◆
Nitazoxanide	◆
Pentamidine	◆
Primaquine	◆
Proguanil	◆
Pyrimethamine	◆
Quinine	■
Sodium stibogluconate	◆
Sulfadoxine	◆
<b>Antipsychotic/Neuroleptics</b>	
Amisulpride	◆
Aripiprazole	■
Asenapine	◆
Cariprazine	▲
Chlorpromazine	◆
Chlorprothixene	◆
Clozapine	◆
Flupentixol	◆
Fluphenazine	◆
Haloperidol	◆
Iloperidone	◆
Levomopromazine	◆
Lurasidone	◆
Olanzapine	◆
Paliperidone	◆
Perazine	◆
Periciazine	◆
Perphenazine	◆
Pimozide	■
Pipotiazine	◆
Prochlorperazine	◆
Promazine	◆
Quetiapine	■
Risperidone	◆
Sulpiride	◆
Thioridazine	◆
Tiapride	◆
Trifluoperazine	◆
Ziprasidone	◆
Zuclopentixol	◆
<b>Antivirals</b>	
Aciclovir	◆
Amantadine	◆
Ansuvimab	◆
Brintofovir	■
Brivudine	◆
Cidofovir	◆
Favipiravir	◆
Foscarnet	◆
Molnupiravir	◆
Nirmatrelvir/ritonavir	●
Oseltamivir	◆
Palivizumab	◆
Remdesivir	◆
Rimantadine	◆
Sotrovimab	◆
Tecovirimat	◆
Tixagevimab/cilgavimab	◆
Valaciclovir	◆
Zanamivir	◆

For personal use only. Not for distribution.

For personal use only. Not for distribution.

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HDV Treatment

Charts created April 2024. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

	Bulevirtide
<b>Anxiolytics/hypnotics/sedatives</b>	
Alprazolam	◆
Amobarbital	◆
Bromazepam	◆
Bromperidol	◆
Buspirone	◆
Clobazam	◆
Clorazepate	◆
Clotiapine	◆
Diazepam	◆
Estazolam	◆
Flurazepam	◆
Lorazepam	◆
Lormetazepam	◆
Midazolam (oral)	■
Midazolam (parenteral)	■
Oxazepam	◆
Quazepam	◆
Temazepam	◆
Triazolam	◆
Zaleplon	◆
Zolpidem	◆
Zopiclone	◆
<b>Beta Blockers</b>	
Atenolol	◆
Bisoprolol	◆
Carvedilol	◆
Celiprolol	◆
Labetalol	◆
Metoprolol	◆
Nebivolol	◆
Oxprenolol	◆
Pindolol	◆
Propranolol	◆
Sotalol	◆
Timolol	◆
<b>Bisphosphonates</b>	
Alendronic acid	◆
Clodronate	◆
Ibandronic acid	◆
Pamidronate	◆
Risedronate	◆
<b>Bronchodilators</b>	
Formoterol	◆
Indacaterol	◆
Ipratropium bromide	◆
Montelukast	◆
Omalizumab	◆
Reslizumab	◆
Salbutamol	◆
Salmeterol	◆
Theophylline	◆
Tiotropium	◆
Umeclidinium bromide	◆
Vilanterol	◆
<b>Calcium Channel Blockers</b>	
Amlodipine	◆
Diltiazem	◆
Felodipine	◆
Nicardipine	◆
Nifedipine	◆
Nisoldipine	◆
Nitrendipine	◆
Verapamil	◆

For personal use only. Not for distribution.

	Bulevirtide
<b>Cancer Therapies</b>	
Abiraterone	◆
Acalabrutinib	◆
Amivantamab	◆
Anastrozole	◆
Apalutamide	◆
Atezolizumab	◆
Avelumab	◆
Axitinib	◆
Belantamab mafodotin	◆
Bevacizumab	◆
Bicalutamide	◆
Blinatumomab	◆
Bortezomib	◆
Bosutinib	◆
Brentuximab vedotin	◆
Capecitabine	◆
Carboplatin	◆
Carfilzomib	◆
Cemiplimab	◆
Cetuximab	◆
Chlorambucil	◆
Cisplatin	◆
Cyclophosphamide	◆
Daratumumab	◆
Dasatinib	◆
Dinutuximab beta	◆
Doxorubicin	◆
Durvalumab	◆
Erlotinib	◆
Elotuzumab	◆
Elranatamab	◆
Enzalutamide	◆
Epcoritamab	◆
Epirubicin	◆
Estramustine	◆
Etoposide	◆
Everolimus	■
Exemestane	◆
Fludarabine	◆
Gefitinib	◆
Gemcitabine	◆
Gemtuzumab ozogamicin	◆
Glofitamab	◆
Hydroxyurea (Hydroxycarbamide)	◆
Idarubicin	◆
Idelalisib	◆
Imatinib	◆
Inotuzumab ozogamicin	◆
Ipilimumab	◆
Irinotecan	◆
Isatuximab	◆
Ixazomib	◆
Lapatinib	◆
Letrozole	◆
Loncastuximab tesirine	◆
Medroxyprogesterone (oncology)	◆
Mercaptopurine	◆
Mesna	◆
Methotrexate	◆
Mitoxantrone	◆
Mogamulizumab	◆
Nilotinib	◆
Niraparib	◆
Nivolumab	◆

For personal use only. Not for distribution.

	Bulevirtide
<b>Cancer Therapies Continued</b>	
Obinutuzumab	◆
Ofatumumab	◆
Olaparib	■
Olaratumab	◆
Oxaliplatin	◆
Paclitaxel	■
Panitumumab	◆
Panobinostat	■
Pembrolizumab	◆
Pertuzumab	◆
Ramucirumab	◆
Retifanlimab	◆
Rituximab	◆
Ruxolitinib	◆
Sacituzumab govitecan	◆
Sunitinib	■
Tamoxifen	◆
Temsirolimus	■
Trastuzumab	◆
Trastuzumab deruxtecan	◆
Trastuzumab emtansine	■
Vinblastine	◆
Vincristine	◆
Vinorelbine	◆

For personal use only. Not for distribution.

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HDV Treatment

Charts created April 2024. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

	Bulevirtide
<b>Contraceptives and hormone replacement</b>	
Conjugated estrogens (HRT)	◆
Desogestrel (POP)	◆
Desogestrel/ethinylestradiol (COC) (>20 µg)	◆
Desogestrel/ethinylestradiol (COC) (≤20 µg)	◆
Dienogest	◆
Drospirenone (POP)	◆
Drospirenone/estradiol (HRT)	◆
Drospirenone/ethinylestradiol (COC) (>20 µg)	◆
Drospirenone/ethinylestradiol (COC) (≤20 µg)	◆
Dydrogesterone/estradiol (HRT)	◆
Estradiol	◆
Ethinylestradiol (>20 µg)	◆
Ethinylestradiol (≤20 µg)	◆
Etonogestrel (implant)	◆
Etonogestrel (vaginal ring)	◆
Gestodene/ethinylestradiol (COC) (>20 µg)	◆
Gestodene/ethinylestradiol (COC) (≤20 µg)	◆
Levonorgestrel (Emergency Contraception)	◆
Levonorgestrel (HRT)	◆
Levonorgestrel (implant)	◆
Levonorgestrel (IUD)	◆
Levonorgestrel (POP)	◆
Levonorgestrel/ethinylestradiol (COC) (>20 µg)	◆
Levonorgestrel/ethinylestradiol (COC) (≤20 µg)	◆
Medroxyprogesterone (depot)	◆
Medroxyprogesterone (oral)	◆
Medroxyprogesterone/conjugated estrogens (HRT)	◆
Medroxyprogesterone/estradiol (HRT)	◆
Micronized progesterone (HRT)	◆
Norelgestromin/ethinylestradiol (patch)	◆
Norethisterone (Norethindrone) (depot injection)	◆
Norethisterone (Norethindrone) (POP)	◆
Norethisterone (Norethindrone)/estradiol (HRT)	◆
Norethisterone (Norethindrone) ethinylestradiol (COC)	◆
Norethisterone (Norethindrone)/mestranol (COC)	◆
Norgestimate/ethinylestradiol (COC)	◆
Norgestrel/conjugated estrogens (HRT)	◆
Norgestrel/ethinylestradiol (COC)	◆
Testosterone	◆
<b>Erectile Dysfunction Agents</b>	
Sildenafil	◆
Tadalafil	◆
Vardenafil	◆

For personal use only. Not for distribution.

	Bulevirtide
<b>Gastrointestinal Agents</b>	
Aluminium hydroxide	◆
Alverine citrate	◆
Antacids	◆
Aprepitant	◆
Bisacodyl	◆
Bismuth subsalicylate	◆
Cimetidine	◆
Cisapride	■
Cyclizine	◆
Docusate sodium	◆
Dantron	◆
Domperidone	■
Droperidol	◆
Esomeprazole	◆
Famotidine	◆
Granisetron	◆
Hyoscine (Scopolamine)	◆
Hyoscine butylbromide	◆
Hyoscine hydrobromide (Scopolamine hydrobromide)	◆
Ispaghula husk	◆
Lactulose	◆
Lafutidine	◆
Lansoprazole	◆
Linacotide	◆
Loperamide	◆
Lubiprostone	◆
Macroglol	◆
Mebeverine	◆
Mesalazine	◆
Methylcellulose	◆
Metoclopramide	◆
Naloxegol	◆
Nizatidine	◆
Omeprazole	◆
Ondansetron	◆
Pantoprazole	◆
Prucalopride	◆
Rabeprazole	◆
Ranitidine	◆
Roxatidine	◆
Senna	◆
Simeticone	◆
Sulfasalazine	●
Trimebutine	◆
Vonoprazan	◆
<b>HCC Therapies</b>	
Atezolizumab + bevacizumab	◆
Lenvatinib	◆
Pembrolizumab	◆
Regorafenib	◆
Sorafenib	◆
<b>Hepatitis B Drugs</b>	
Adefovir	◆
Entecavir	◆
Lamivudine	◆
Peginterferon alfa-2a	◆
Peginterferon alfa-2b	◆
Ribavirin	◆
Telbivudine	◆
Tenofovir alafenamide	◆
Tenofovir-DF	◆
<b>Hepatitis C Drugs</b>	
Daclatasvir	◆
Elbasvir/Grazoprevir	■
Glecaprevir/Pibrentasvir	■
Ledipasvir/Sofosbuvir	◆
OBV/PTV/r	●
OBV/PTV/r + Dasabuvir	●
Lamivudine	◆
Ribavirin	◆
Sofosbuvir (SOF)	◆
SOF/Velpatasvir	◆
SOF/Velpatasvir/Voxilaprevir	■

For personal use only. Not for distribution.

	Bulevirtide
<b>Herbals/Supplements/Vitamins</b>	
Aloe vera	◆
Ascorbic acid (Vitamin C)	◆
Black cohosh ( <i>A. racemosa</i> )	◆
Cat's claw ( <i>U. tomentosa</i> )	◆
Colecalciferol (Vitamin D3)	◆
Cyanocobalamin (B12)	◆
Diosmin	◆
Echinacea	◆
Enteral feeds	◆
Eucalyptus globulus	◆
Ferrous sulfate	◆
Folic acid	◆
Garlic	◆
Ginger ( <i>Z. officinale</i> )	◆
Ginkgo biloba	◆
Ginseng	◆
Goldenseal ( <i>H. canadensis</i> )	◆
Grape seed extract	◆
Grapefruit juice	◆
Green tea ( <i>C. sinensis</i> )	◆
Homeopathic remedies	◆
Inula racemosa	◆
Iodine	◆
Kava kava ( <i>P. methysticum</i> )	◆
L-lysine	◆
Milk thistle	◆
Niacin (Vitamin B3)	◆
Omega-3-6-9 fatty acids	◆
Oral nutritional supplements	◆
Oregano oil	◆
Retinol (Vitamin A)	◆
Riboflavin (Vitamin B2)	◆
Saw palmetto ( <i>S. repens</i> )	◆
St John's wort	◆
Thiamine (Vitamin B1)	◆
Turmeric (curcumin)	◆
Valerian	◆
Vitamin E	◆
Zinc	◆
<b>HIV Drugs</b>	
<b>Entry/Integrase Inhibitors</b>	
Albuvirtide	◆
Bictegravir/FTC/TAF	◆
Cabotegravir (oral)	◆
Cabotegravir/rilpivirine (LA)	▲
Dolutegravir	◆
Dolutegravir/rilpivirine	▲
Elvitegravir/cobi /FTC/TAF	●
Elvitegravir/cobi/FTC/TDF	●
Enfuvirtide	◆
Fostemsavir	◆
Ibalizumab-uiyk	◆
Maraviroc	▲
Raltegravir	◆
<b>NRTIs</b>	
Dapivirine	◆
Doravirine	▲
Doravirine/3TC/TDF	▲
Efavirenz	●
Etravirine	◆
Nevirapine	◆
Rilpivirine	▲
Rilpivirine/dolutegravir	▲
Rilpivirine/FTC/TAF	▲
<b>NRTIs</b>	
Abacavir	◆
Didanosine	◆
Emtricitabine (FTC)	◆
Emtricitabine + TAF	◆
Emtricitabine + TDF	◆
Lamivudine	◆
Stavudine	◆
Tenofovir-DF	◆
Zidovudine	◆
<b>Protease Inhibitors</b>	
Atazanavir alone	●
Atazanavir/cobicistat	●
Atazanavir + ritonavir	●
Darunavir/cobicistat	●
Darunavir/cobi/FTC/TAF	●
Darunavir + ritonavir	●
Fosamprenavir	●
Indinavir	●
Lopinavir	●

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HDV Treatment

Charts created April 2024. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

Ritonavir	●
Tipranavir	●

For personal use only. Not for distribution.

	Bulevirtide
<b>Hypertension/Heart Failure Agents</b>	
Acebutolol	◆
Aliskiren	◆
Ambrisentan	■
Amiloride	◆
Azilsartan	◆
Benazepril	◆
Bendroflumethiazide	◆
Bosentan	■
Bumetanide	◆
Candesartan	◆
Captopril	◆
Chlorothiazide	◆
Chlortalidone	◆
Cilazapril	◆
Clevidipine	◆
Clonidine	◆
Doxazosin	◆
Enalapril	◆
Eplerenone	◆
Epoprostenol	◆
Eprosartan	◆
Fosinopril	◆
Furosemide	◆
Hydralazine	◆
Hydrochlorothiazide	◆
Iloprost	◆
Indapamide	◆
Irbesartan	●
Isradipine	◆
Ivabradine	◆
Lacidipine	◆
Lercanidipine	◆
Lisinopril	◆
Losartan	◆
Macitentan	◆
Methyldopa	◆
Metolazone	◆
Moxonidine	◆
Olmesartan	■
Perindopril	◆
Prazosin	◆
Quinapril	◆
Ramipril	◆
Ranolazine	◆
Rilmenidine	◆
Riociguat	◆
Sacubitril/valsartan	■
Selexipag	◆
Sildenafil	◆
Spirololactone	◆
Tadalafil	◆
Telmisartan	■
Torasemide	◆
Trandolapril	◆
Treprostinil	◆
Valsartan	■
Xipamide	◆
Zofenopril	◆
<b>Illicit/Recreational</b>	
Alcohol	◆
Amphetamine	◆
Cannabis	◆
Carfentanil	■
Cocaine	◆
Ecstasy (MDMA)	◆
Etizolam	◆
Fentanyl (Recreational)	■
GHB (Gamma-hydroxybutyrate)	■
Heroin	◆
LSD (Lysergic acid diethylamide)	◆
Mephedrone	◆
Methamphetamine	◆
Phencyclidine (PCP)	■

For personal use only. Not for distribution.

	Bulevirtide
<b>Hypertension/Heart Failure Agents</b>	
Acebutolol	◆
Aliskiren	◆
Ambrisentan	■
Amiloride	◆
Azilsartan	◆
Benazepril	◆
Bendroflumethiazide	◆
Bosentan	■
Bumetanide	◆
Candesartan	◆
Captopril	◆
Chlorothiazide	◆
Chlortalidone	◆
Cilazapril	◆
Clevidipine	◆
Clonidine	◆
Doxazosin	◆
Enalapril	◆
Eplerenone	◆
Epoprostenol	◆
Eprosartan	◆
Fosinopril	◆
Furosemide	◆
Hydralazine	◆
Hydrochlorothiazide	◆
Iloprost	◆
Indapamide	◆
Irbesartan	●
Isradipine	◆
Ivabradine	◆
Lacidipine	◆
Lercanidipine	◆
Lisinopril	◆
Losartan	◆
Macitentan	◆
Methyldopa	◆
Metolazone	◆
Moxonidine	◆
Olmesartan	■
Perindopril	◆
Prazosin	◆
Quinapril	◆
Ramipril	◆
Ranolazine	◆
Rilmenidine	◆
Riociguat	◆
Sacubitril/valsartan	■
Selexipag	◆
Sildenafil	◆
Spirololactone	◆
Tadalafil	◆
Telmisartan	■
Torasemide	◆
Trandolapril	◆
Treprostinil	◆
Valsartan	■
Xipamide	◆
Zofenopril	◆
<b>Illicit/Recreational</b>	
Alcohol	◆
Amphetamine	◆
Cannabis	◆
Carfentanil	■
Cocaine	◆
Ecstasy (MDMA)	◆
Etizolam	◆
Fentanyl (Recreational)	■
GHB (Gamma-hydroxybutyrate)	■
Heroin	◆
LSD (Lysergic acid diethylamide)	◆
Mephedrone	◆
Methamphetamine	◆
Phencyclidine (PCP)	■

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HDV Treatment

Charts created April 2024. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

	Bulevirtide
<b>Immunosuppressants</b>	
Adalimumab	◆
Alemtuzumab	◆
Anakinra	◆
Azathioprine	◆
Baricitinib	◆
Basiliximab	◆
Belimumab	◆
Brodalumab	◆
Canakinumab	◆
Ciclosporin	●
Eculizumab	◆
Etanercept	◆
Fingolimod	◆
Golimumab	◆
Guselkumab	◆
Infliximab	◆
Ixekizumab	◆
Lenalidomide	◆
Mirikizumab	◆
Mycophenolate	◆
Natalizumab	◆
Pirfenidone	◆
Ravulizumab	◆
Risankizumab	◆
Sarilumab	◆
Secukinumab	◆
Sirolimus	■
Siltuximab	◆
Tildrakizumab	◆
Tocilizumab	◆
Tralokinumab	◆
Tacrolimus	■
Upadacitinib	◆
Ustekinumab	◆
Vedolizumab	◆
<b>Lipid Lowering Agents</b>	
Alirocumab	◆
Atorvastatin	■
Bezafibrate	◆
Evolocumab	◆
Ezetimibe	●
Fenofibrate	◆
Fish oils	◆
Fluvastatin	■
Gemfibrozil	◆
Lovastatin	■
Pitavastatin	■
Pravastatin	■
Rosuvastatin	■
Simvastatin	■
<b>Oxytocics</b>	
Ergometrine (ergonovine)	■
Mifepristone	◆
Misoprostol	◆

For personal use only. Not for distribution.

	Bulevirtide
<b>Parkinsonism Agents</b>	
Benzotropine	◆
Carbidopa	◆
Orphenadrine	◆
Pramipexole	◆
Procyclidine	◆
Rasagiline	◆
Ropinirole	◆
<b>PBC Agents</b>	
Obeticholic acid	◆
Ursodeoxycholic acid	◆
<b>Steroids</b>	
Beclometasone	◆
Betamethasone	◆
Budesonide	◆
Ciclesonide	◆
Clobetasol (topical)	◆
Clobetasone (topical)	◆
Dexamethasone ≤16 mg	◆
Dexamethasone >16 mg	◆
Fludrocortisone	◆
Flunisolide	◆
Fluticasone	◆
Hydrocortisone (topical)	◆
Methylprednisolone	◆
Mometasone	◆
Prednicarbate	◆
Prednisone	◆
Triamcinolone	◆
<b>Urological Agents</b>	
Alfuzosin	◆
Desmopressin	◆
Dutasteride	◆
Finasteride	◆
Mirabegron	◆
Sildenafil	◆
Solifenacin	◆
Tamsulosin	◆
Tolterodine	◆

For personal use only. Not for distribution.

	Bulevirtide
<b>Other Drugs</b>	
Acamprosate	◆
Acetazolamide	◆
Acitretin	◆
Activated charcoal	◆
Allopurinol	◆
Atomoxetine	◆
Atropine	◆
Baclofen	◆
Bamlanivimab/Etesevimab	◆
Benralizumab	◆
Betahistine	◆
Bimatoprost	◆
Biperiden	◆
Brinzolamide	◆
Brolucizumab	◆
Bromocriptine	◆
Burosumab	◆
Calcitonin	◆
Calcium carbimide	◆
Calcium resonium	◆
Cannabidiol (CBD)	◆
Carbamazole	◆
Carisoprodol	◆
Casirivimab/imdevimab	◆
Cilostazol	◆
Clomifene	◆
Colchicine	■
Colestyramine	◆
Conivaptan	◆
Convalescent plasma (COVID-19)	◆
COVID-19 vaccines	◆
Crizanlizumab	◆
Cyclobenzaprine	◆
Cyproterone acetate	▲
Cytisine	◆
Darbepoetin	◆
Deferiprone	◆
Denosumab	◆
Dexamfetamine	◆
Dextromethorphan	◆
Disulfiram	◆
Donepezil	◆
Dorzolamide	◆
Dupilumab	◆
Eliglustat	◆
Emicizumab	◆
Epoetin alfa	◆
Etelcalcetide	◆
Faricimab	◆
Febuxostat	◆
Filgrastim	◆
Filbanserin	◆
Gadopentetate (gadolinium)	◆
Glycerol phenylbutyrate	◆
Goserelin acetate	◆
Guanfacine	▲
Idarucizumab	◆
Influenza vaccine	◆
Interferon beta	◆
Isosorbide mononitrate	◆
Isotretinoin	◆
Lanadelumab	◆
Lanreotide	◆
Lebrikizumab	◆
Leuprorelin acetate	◆
Levothyroxine	■
Lisdexamfetamine	◆
Lofexidine	◆
Lumacaftor/ivacaftor	◆
Magnesium	◆
Melatonin	◆
Memantine	◆
Mepolizumab	◆
Methimazole (Thiamazole)	◆
Methylphenidate	◆
Minoxidil	◆
Modafinil	◆

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HDV Treatment

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

Other Drugs Continued	Bulevirtide
Naftidrofuryl	◆
Nalmefene	◆
Naloxone	◆
Naltrexone	◆
Neostigmine	◆
Nicorandil	◆
Nusinersen	◆
Ocrelizumab	◆
Orlistat	◆
Penicillamine	◆
Pentoxifylline	◆
Phenylephrine	◆
Pilocarpine	◆
Piracetam	◆
Potassium	◆
Propylthiouracil	◆
Protamine sulphate	◆
Pseudoephedrine	◆
Pyridostigmine	◆
Raloxifene	◆
Romozosumab	◆
Rozanolixizumab	◆
Sevelamer	◆
Strontium ranelate	◆
Thalidomide	◆
Triptorelin	◆
Varenicline	◆

For personal use only. Not for distribution. For personal use only. Not for distribution.

For personal use only. Not for distribution. For personal use only. Not for distribution.

### Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

### Notes

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.